Passage Bio and Remix Therapeutics Agree to Merge Into One Company
Passage Bio and Remix Therapeutics have struck a merger deal. The combined entity will operate under the Remix Therapeutics name and push forward a small molecule RNA pipeline.
Passage Bio and Remix Therapeutics announced a definitive merger agreement that will consolidate the two biotech firms into a single publicly traded company operating under the Remix Therapeutics name, the companies disclosed Wednesday via GlobalNewswire.
The merged organization will focus its resources on advancing Remix's existing pipeline of novel small molecule therapies. Those treatments are engineered to reprogram RNA processing — a cutting-edge approach that targets the underlying biological mechanisms driving disease rather than managing symptoms downstream.
Read more UK Tribunal Clears $4 Billion Apple iCloud Class Action →
RNA processing represents a relatively new frontier in drug development, and the merger signals a strategic bet that small molecule interventions at this level can unlock treatments for conditions that have resisted conventional approaches. By combining under one roof, the companies appear to be consolidating capital and operational infrastructure to accelerate that science toward clinical milestones.
Passage Bio had previously built its identity around gene therapy for neurological diseases, making the pivot toward Remix's RNA-focused platform a notable strategic shift. The deal underscores a broader consolidation trend in the biotech sector as smaller companies seek scale amid a challenging funding environment.
Terms of the transaction, including share structure and expected close date, were not detailed in the initial announcement. Continue reading at GlobalNewswire.
